
CLAIMS

[Claim 1]

Use of an antibody-drug conjugate and an immune checkpoint inhibitor for the manufacture of a medicament for a therapeutic method for treating cancer wherein the antibody-drug conjugate and the immune checkpoint inhibitor are to be administered in combination, and the antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula:



wherein A represents the connecting position to an antibody,
is conjugated to the antibody via a thioether bond.

[Claim 2]

The use according to claim 1, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.

[Claim 3]

The use according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[Claim 4]

The use according to claim 2 or 3, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO: 2.

[Claim 5]

The use according to claim 2 or 3, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence represented by SEQ ID NO: 1 and a light chain consisting of the amino acid sequence represented by SEQ ID NO: 2.

[Claim 6]

The use according to any one of claims 1 to 5, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 2 to 8.

[Claim 7]

The use according to any one of claims 1 to 5, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.

[Claim 8]

The use according to any one of claims 1 to 5, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7.5 to 8.

[Claim 9]

The use according to any one of claims 1 to 8, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.

[Claim 10]

The use according to claim 9, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.

[Claim 11]

The use according to claim 9, wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody.

[Claim 12]

The use according to claim 9, wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody.

[Claim 13]

The use according to any one of claims 1 to 12, wherein the antibody-drug conjugate and the immune checkpoint inhibitor are separately contained as active components in different formulations, and are to be administered simultaneously or at different times.

[Claim 14]

The use according to any one of claims 1 to 12, wherein the antibody-drug conjugate and the immune checkpoint inhibitor are contained as active components in a single formulation and to be administered.

[Claim 15]

The use according to any one of claims 1 to 14, wherein the cancer is at least one selected from the group consisting of lung cancer, urothelial cancer, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, esophagogastric junction adenocarcinoma, gastrointestinal stromal tumor, uterine cervix cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular cancer, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulval cancer, thyroid cancer, penis cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head-and-neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.

[Claim 16]

The use according to claim 15, wherein the cancer is colorectal cancer.

[Claim 17]

The use according to claim 15, wherein the cancer is breast cancer.

[Claim 18]

The use according to claim 15, wherein the cancer is lung cancer.

[Claim 19]

The use according to claim 15, wherein the cancer is urothelial cancer.

[Claim 20]

The use according to claim 15, wherein the cancer is bladder cancer.

[Claim 21]

The use according to claim 15, wherein the cancer is gastric cancer.

[Claim 22]

The use according to claim 15, wherein the cancer is esophagogastric junction adenocarcinoma.

[Claim 23]

The use according to any one of claims 1 to 22, wherein the antibody-drug conjugate has an antitumor immunity-activating effect.

[Claim 24]

The use according to any one of claims 1 to 23, wherein the antibody-drug conjugate has at least one effect selected from the group consisting of:

(1) a promoting effect on growth of intratumor CD8-positive T cells; and

(2) an activating effect on intratumor CD8-positive T cells.

[Claim 25]

The use according to any one of claims 1 to 24, wherein the antibody-drug conjugate has a promoting effect on the formation of immune memory against tumor.

[Claim 26]

The use according to claim 25, wherein the tumor is expressing an antigen for the antibody in the antibody-drug conjugate.

[Claim 27]

The use according to claim 25, wherein a part of the cells of the tumor are not expressing an antigen for the antibody in the antibody-drug conjugate.

[Claim 28]

The use according to any one of claims 1 to 27, wherein the antibody-drug conjugate has at least one effect selected from the group consisting of:

(1) a promoting effect on increase of the number of dendritic cells in a tumor;

(2) an activating effect on dendritic cells; and


(3) a promoting effect on elevation of the expression level of MHC class I on cancer cells.

[Claim 29]

The use according to any one of claims 1 to 28, wherein the immune checkpoint inhibitor deactivates an immunosuppression signal generated through elevation of the expression level of PD-L1 on cancer cells promoted by the antibody-drug conjugate, and thereby the antibody-drug conjugate exhibits a higher antitumor effect.

[Claim 30]

Use of an antibody-drug conjugate for the manufacture of a medicament for a therapeutic method for treatment of a disease that can be ameliorated through an antitumor immunity-activating effect wherein the antibody-drug conjugate is to be administered, and the antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula:



wherein A represents the connecting position to an antibody,

is conjugated to the antibody via a thioether bond,

wherein the antibody-drug conjugate has a promoting effect on the formation of immune memory against tumor,

wherein the disease is at least one selected from the group consisting of lung cancer, urothelial cancer, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, esophagogastric junction adenocarcinoma, gastrointestinal stromal tumor, uterine cervix cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular cancer, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulval cancer, thyroid cancer, penis cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head-and-neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.

[Claim 31]

The use according to claim 30, wherein the antibody-drug conjugate has at least one effect selected from the group consisting of:

(1) a promoting effect on growth of intratumor CD8-positive T cells; and

(2) an activating effect on intratumor CD8-positive T cells.

[Claim 32]

The use according to claim 30 or 31, wherein the tumor is expressing an antigen for the antibody in the antibody-drug conjugate.

[Claim 33]

The use according to claim 30 or 31, wherein a part of the cells of the tumor are not expressing an antigen for the antibody in the antibody-drug conjugate.

[Claim 34]

The use according to any one of claims 30 to 33, wherein the antibody-drug conjugate has at least one effect selected from the group consisting of:

(1) a promoting effect on increase of the number of dendritic cells in a tumor;

(2) an activating effect on dendritic cells; and

(3) a promoting effect on elevation of the expression level of MHC class I on cancer cells.

[Claim 35]

The use according to any one of claims 30 to 34, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.

[Claim 36]

The use according to claim 35, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[Claim 37]

The use according to claim 35 or 36, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light

chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO: 2.

[Claim 38]

The use according to claim 35 or 36, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence represented by SEQ ID NO: 1 and a light chain consisting of the amino acid sequence represented by SEQ ID NO: 2.

[Claim 39]

The use according to any one of claims 30 to 38, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 2 to 8.

[Claim 40]

The use according to any one of claims 30 to 38, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.

[Claim 41]

The use according to any one of claims 30 to 38, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7.5 to 8.

[Claim 42]

The use according to any one of claims 30 to 41, wherein the disease is colorectal cancer.

[Claim 43]

The use according to any one of claims 30 to 41, wherein the disease is breast cancer.

[Claim 44]

The use according to any one of claims 30 to 41, wherein the disease is lung cancer.

[Claim 45]

The use according to any one of claims 30 to 41, wherein the disease is urothelial cancer.

[Claim 46]

The use according to any one of claims 30 to 41, wherein the disease is bladder cancer.

[Claim 47]


The use according to any one of claims 30 to 41, wherein the disease is gastric cancer.

[Claim 48]

The use according to any one of claims 30 to 41, wherein the disease is esophagogastric junction adenocarcinoma.

[Claim 49]

Use of an antibody-drug conjugate for the manufacture of a medicament for a therapeutic method for treatment of a disease that can be ameliorated through an antitumor immunity-activating effect wherein the therapeutic method releases the compound represented by the following formula:



in a tumor,

wherein the compound has a promoting effect on the formation of immune memory against tumor,

wherein the disease is at least one selected from the group consisting of lung cancer, urothelial cancer, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, esophagogastric junction adenocarcinoma, gastrointestinal stromal tumor, uterine cervix cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular cancer, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulval cancer, thyroid cancer, penis cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head-and-neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.

[Claim 50]

The use according to claim 49, wherein the compound has at least one effect selected from the group consisting of:

(1) a promoting effect on growth of intratumor CD8-positive T cells; and

(2) an activating effect on intratumor CD8-positive T cells.

[Claim 51]

The use according to claim 49 or 50, wherein the compound has at least one effect selected from the group consisting of:

(1) a promoting effect on increase of the number of dendritic cells in a tumor;

(2) an activating effect on dendritic cells; and

(3) a promoting effect on elevation of the expression level of MHC class I on cancer cells.